Details and AGREE II ratings of clinical practice guidelines that met eligibility criteria
| Organisation | Region | Included | Publication year | AGREE II ratings of each reviewer separately | |||||||||
| 4 | 7 | 8 | 10 | 12 | 13 | 15 | 22 | 23 | Total | ||||
| AAO18 | USA | Yes | 2017 | 7 | 7 | 3 | 5 | 6 | 6 | 5 | 7 | 7 | 53 |
| 7 | 7 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 57 | ||||
| AOA19 | USA | Yes | 2017 | 7 | 4 | 7 | 6 | 7 | 7 | 6 | 7 | 4 | 55 |
| 7 | 6 | 7 | 7 | 7 | 7 | 7 | 7 | 5 | 60 | ||||
| NHMRC17 | AUS | Yes | 2010 | 7 | 4 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | 51 |
| 7 | 4 | 6 | 5 | 5 | 5 | 5 | 6 | 6 | 49 | ||||
| Anwar et al26 | USA | No | 2013 | 4 | 1 | 1 | 2 | 5 | 4 | 4 | 2 | 6 | 29 |
| 4 | 1 | 1 | 1 | 3 | 4 | 3 | 2 | 5 | 24 | ||||
| EGS27 | EU | No | 2014 | 7 | 2 | 2 | 4 | 5 | 3 | 5 | 4 | 4 | 3 |
| 6 | 4 | 5 | 4 | 6 | 5 | 5 | 5 | 4 | 44 | ||||
| SOS28 | SE | No | 2012 | 6 | 3 | 6 | 2 | 5 | 4 | 5 | 3 | 5 | 39 |
| 6 | 3 | 5 | 2 | 2 | 4 | 5 | 4 | 4 | 35 | ||||
Titles of the AGREE II items are as follows: 4—the guideline development groups include individuals from all relevant professional groups; 7—systematic methods were used to search for evidence; 8—the criteria for selecting the evidence are clearly described; 10—the methods for formulating the recommendations are clearly described; 12—there is an explicit link between the recommendations and the supporting evidence; 13—the guidelines has been externally reviewed by experts prior to publication; 15—the recommendations are specific and unambiguous; 22—the views of the funding body do not influence the content of the guideline; 23—competing interests of guideline development group members have been recorded and addressed.
AAO, American Academy of Ophthalmology; AGREE II, Appraisal of Guidelines for Research and Evaluation II; AOA, American Optometric Association; AUS, Australia; EGS, European Glaucoma Society; EU, Europe; NHMRC, National Health and Medical Research Council; SE, Sweden; SOS, Swedish Ophthalmolgical Society.